- $2.10bn
- $1.94bn
- $276.26m
Vericel, MediWound climb on FDA's expanded approval for skin treatment
Brief: Vericel Announces FDA Approval Of Nexobrid
Brief: Vericel Q2 EPS USD -0.1
Vericel Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: Vericel Appoints Karen Mahoney As Chief Human Resources Officer
Vericel Corp reports results for the quarter ended in March - Earnings Summary
Brief: Vericel Q1 EPS USD -0.08
Vericel Corp reports results for the quarter ended in December - Earnings Summary
Brief: Vericel Q4 Net Income USD 13 Million
Vericel Corp expected to post earnings of 17 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Humana, Boeing, Tesla
Vericel hits over 2-year high as Truist upgrades to 'buy', hikes PT
Brief: Vericel Announces Preliminary Full-Year And Q4 2023 Financial Results
U.S. RESEARCH ROUNDUP-Boot Barn Holdings, Hershey Co, Ulta Beauty
Brief: Vericel Q3 Net Income USD -3.7 Million
MediWound and Vericel up on U.S. availability of their burn medication
Brief: Vericel Announces U.S. Commercial Availability Of Nexobrid® (Anacaulase-Bcdb) For The Treatment Of Severe Thermal Burns In Adults
Vericel Corp reports results for the quarter ended in June - Earnings Summary
Brief: Vericel Q2 Net Income USD -5 Million